Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer

Table 1 Correlation between the M2 isoform of pyruvate kinase expression and clinicopathologic characteristics of gastric cancer patients n (%)

Characteristics		M2 isoform of pyruvate kinase expression
	Total (n = 368)	Negative (n = 224)	Positive (n = 144)	P
Median follow-up (70.6 mo)
Relapse	143 (39.0)
Death	138 (37.7)
Adjuvantchemotherapy	243 (66.0)
Age (yr)				0.027
≤ 60	230	150 (65.2)	80 (34.8)
> 60	138	74 (53.6)	64 (46.4)
Gender				0.263
Male	222	130 (58.6)	92 (41.4)
Female	146	94 (64.4)	52 (35.6)
AJCC 7th stage				0.811
I	105	67 (63.8)	38 (36.2)
II	89	51 (57.3)	38 (42.7)
III	172	105 (61.0)	67 (39.0)
IV	2	1 (50.0)	1 (50.0)
T stage				0.009
T1	94	62 (65.9)	32 (34.1)
T2	42	30 (71.4)	12 (28.6)
T3	87	40 (45.9)	47 (54.1)
T4	145	92 (63.4)	53 (36.6)
N stage				0.086
N0	131	80 (61.1)	51 (38.9)
N1	62	33 (53.2)	29 (46.8)
N2	69	37 (53.6)	32 (46.4)
N3	106	74 (69.8)	32 (30.2)
Histology				< 0.001
Welldifferentiatedadenocarcinoma	22	8 (36.4)	14 (63.6)
Moderatelydifferentiatedadenocarcinoma	96	39 (40.6)	57 (59.4)
Poorlydifferentiatedadenocarcinoma	143	91 (63.6)	52 (36.4)
Signetringcellcarcinoma	79	65 (82.3)	14 (17.7)

AJCC: American Joint Committee on Cancer; T: Tumor; N: Node.